跳转到主页内容
访问键 NCBI主页 myncbi主页 主要内容 主导航
临床试验
1999年8月; 160(2):600-7。
doi: 10.1164 / ajrccm.160.2.9810008。

吸入前列环素和伊洛前列素治疗肺纤维化继发严重肺动脉高压

隶属关系
临床试验

吸入前列环素和伊洛前列素治疗肺纤维化继发严重肺动脉高压

H Olschewski.et al。 呼吸危重症护理医学杂志 1999年8月

抽象的

肺动脉高压是肺纤维化的危及生命并发症。由于系统副作用和肺通气灌注失配血管扩张剂疗法难以。我们将静脉内前列腺和吸入NO和吸气前列腺素的影响与随机顺序进行了比较,并且此外,在肺纤维化和肺动脉高压患者中测试了氧气和全身钙拮抗剂(CAAs)的影响。雾化前列腺素(PG)I(2)引起优先的肺血管扩张,其平均肺动脉压力降低了44.1 +/- 4.2至31.6 +/- 3.1mm Hg,以及来自810 +/-226的肺血管阻力(RL)386 +/- 69 Dyn。s。cm( - )(5)(分别为p <0.05)。通过多重惰性气体分析测量的全身动脉压,动脉氧饱和度和肺右侧分流流量没有显着改变。没有类似地导致选择性肺化血管扩张,R1从726 +/- 217〜458 +/- 81达克递减。s。 cm(-)(5). In contrast, both intravenous PGI(2) and CAAs were not pulmonary selective, resulting in a significant drop in arterial pressure. In addition, PGI(2) infusion caused a marked increase in shunt flow. Long-term therapy with aerosolized iloprost (long-acting PGI(2) analog) resulted in unequivocal clinical improvement from a state of immobilization and severe resting dyspnea in a patient with decompensated right heart failure. We concluded that, in pulmonary hypertension secondary to lung fibrosis, aerosolization of PGI(2) or iloprost causes marked pulmonary vasodilatation with maintenance of gas exchange and systemic arterial pressure. Long-term therapy with inhaled iloprost may be life saving in decompensated right heart failure from pulmonary hypertension secondary to lung fibrosis.

类似的文章

被引用48文章

发布类型

网格计算

LinkOut -更多资源